Determination of enzalutamide long-term safety and efficacy for castration-resistant prostate cancer patients after combined anti-androgen blockade followed by alternative anti-androgen therapy: a multicenter prospective DELC study.

Akira NagaharaMotohide UemuraMototaka SatoWataru NakataMasao TsujihataTetsuya TakaoSoichi MatsumuraKensaku NishimuraShingo TakadaToshichika IwanishiYasuyuki KobayashiYu IshizuyaTsuyoshi TakadaKoichi OkadaHitoshi InoueTaigo KatoKoji HatanoAtsunari KawashimaTakeshi UjikeKazutoshi FujitaNorio Nonomura

Published in: Japanese journal of clinical oncology (2024)

In the DELC study, the safety of enzalutamide was comparable to that in previous reports. Serum levels of neuron-specific enolase and interleukin-6 were suggested as prognostic factors for castration-resistant prostate cancer with potential clinical utility.

Keyphrases

prognostic factors
prostate cancer
ejection fraction
newly diagnosed
emergency department
stem cells
clinical trial
high resolution
patient reported outcomes
solid phase extraction
molecularly imprinted